The new genetics: The new genetics in clinical practice

British Medical Journal

Volumn 316, Issue 7131, 1998, Pages 618-620

  Bell, John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; NEW DRUG;

ALLELE; ALZHEIMER DISEASE; BIOCHEMISTRY; BREAST CANCER; CLINICAL GENETICS; CLINICAL PRACTICE; COLON CANCER; CYSTIC FIBROSIS; DISEASE COURSE; DRUG DESIGN; EARLY DIAGNOSIS; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HEPATITIS; HUMAN; KIDNEY POLYCYSTIC DISEASE; MOLECULAR GENETICS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; CLASSIFICATION; DISEASE PREDISPOSITION; GENE; MEDICAL GENETICS; PHARMACEUTICS; REVIEW; RISK FACTOR;

CLASSIFICATION; DISEASE SUSCEPTIBILITY; GENES; GENETICS, MEDICAL; HUMANS; RISK FACTORS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0032554222     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.316.7131.618     Document Type: Short Survey

References (19)

1. Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahen R, Grzelcak Z, et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 1989;245:1066-73.
2. European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within n duplicated region on chromosome 16. Cell 1994;77:881-6.
3. Schuler GD, Boguski MS, Stewart EA, Stein LD, Gyapay G, Rice K, et al. A gene map of the human genome. Science 1996;274:540-6.
4. Marshall E. Genome researchers lake the pledge. Science 1996;272:477-8.
5. To affinity . . . and beyond [editorial]. Nature Genet 1996;14:367-70.
6. Ludworth AG, Woodrow JC. HL-A antigens and diabetes mellitus. Lancet 1974;2:1153.
7. Miki Y, Swensen J, Shattuck-Eidens D, Fureal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRACT. Science 1994;266:66-71.
8. Wooster R, Bignell G, Lancester J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
9. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
10. Yamagata K, Hiroto F, Oda N, Kaisaka PJ, Menzel S, Cos NJ, et al. Mutations in the hepatocyte nuclear factor-4a gene in maturity-onset diabetes of the young (MODY1). Nature 1996;384:458-60.
11. Froguel F, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, et al. Familial hyperglycemia due to mutations in glycokinase: definition of a subtype of diabetes mellitus. N Engl J Med 1993;328:697-702.
12. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the hepatocyte nuclear factor-1a gene in maturity-onset diabetes of the young (MODY3). Nature 1996;384:455-8.
13. Roses A. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol 1995;38:6-14.
14. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
15. Jeunemaitre X, Saubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-80.
16. Schmidt S, Schone N, Ritz E. Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int 1995;47:1176-81.
17. Ridker PM, Miletick JP, Stampfer MJ, Goldhaber SZ, Linkpainter K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2.
18. Nebert DW. Polymorphisms in drug-metabolising enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 997;60:265-71.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effects of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.